The present study identifies a CAF-derived IGF1/IGF1R axis-constrained physiologically by the phosphatase PTPN9-as a central driver of CCA growth and, critically, of resistance to the multi-target TKI surufatinib. Here, PTPN9 is linked to cholangiocarcinoma.